Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baodong Qin
• Treatments: Afatinib; Dabrafenib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Olaparib; Palbociclib; Sirolimus; Trastuzumab; Vemurafenib

Criteria

Inclusion Criteria:

• Malignant solid tumors diagnosed histologically;

• Common solid tumor patients have no any standard choice after multiple line of therapy; Rare solid tumor did not have any standard recommended treatment;

• Expected survival ≥ 1 month;

• ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL <1.5 times the upper limit of normal (ULN); Liver ALT and AST <2.5 × ULN and if liver metastases, ALT and AST <5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min

Exclusion Criteria:

• Patient still has standard treatment therapy based on NCCN guidance;

• Patient can not comply with research program requirements or follow-up;